View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
December 22, 2010

Biomet Completes Patient Enrolment for Tennis Elbow Treatment Study

Biomet subsidiary Biomet Biologics has completed the required patient enrolment of 230 subjects for a clinical trial to evaluate the use of the Recover Kit for the treatment of chronic tennis elbow. The Recover Kit works by producing autologous platelet-rich plasma to treat the injury.

By cms admin

Biomet subsidiary Biomet Biologics has completed the required patient enrolment of 230 subjects for a clinical trial to evaluate the use of the Recover Kit for the treatment of chronic tennis elbow.

The Recover Kit works by producing autologous platelet-rich plasma to treat the injury.

The multicentre, prospective, randomised, controlled and double-blind clinical trial is being performed under a US Food and Drug Administration (FDA)-approved investigational device exemption to evaluate the safety and efficacy of the Recover Kit.

Study subjects will receive either the investigational platelet-rich plasma treatment or an active control (bupivacaine), and the study will compare adverse event profiles and clinical assessments of pain and function in the two groups.

The trial will be completed when the last subject enrolled will reach 24 weeks follow up in mid-2011.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Get important industry news and analysis sent to your inbox
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Hospital Management